Javascript must be enabled to continue!
Structural and dynamic studies uncover a distinct allosteric modulatory site at the mu-opioid receptor
View through CrossRef
Positive allosteric modulators (PAMs) of the μ opioid receptor (MOR) offer a promising path toward safer opioid therapeutics, yet their mechanisms of action remain poorly understood. Here, we uncover the structural and mechanistic basis of BMS-986187, a chemically distinct MOR PAM with in vivo efficacy, using an integrated approach combining cryogenic electron microscopy (cryo-EM), molecular dynamics (MD) simulations, signaling assays, and site-directed mutagenesis. We identify a previously uncharacterized allosteric site for BMS-986187, a lipid-facing pocket formed by MOR transmembrane helices 2, 3, and 4, distinct from sites occupied by other known MOR PAMs or negative allosteric modulators. BMS-986187 engages both receptor residues and a neighboring cholesterol molecule, suggesting a cooperative ligand-lipid mechanism. Our studies pinpoint residues essential for allosteric modulation, while information-theory analysis of MD trajectories uncovers specific allosteric communication pathways linking the PAM site to both the orthosteric agonist DAMGO and the G protein interface. Together, these findings redefine the landscape of MOR allosteric modulation by revealing a novel binding site, a potentially lipid-sensitive allosteric mechanism, and the molecular wiring of long-range communication within MOR. This work provides a new molecular framework for the rational design of PAMs targeting opioid receptors with improved precision and possible therapeutic potential.
Cold Spring Harbor Laboratory
Title: Structural and dynamic studies uncover a distinct allosteric modulatory site at the mu-opioid receptor
Description:
Positive allosteric modulators (PAMs) of the μ opioid receptor (MOR) offer a promising path toward safer opioid therapeutics, yet their mechanisms of action remain poorly understood.
Here, we uncover the structural and mechanistic basis of BMS-986187, a chemically distinct MOR PAM with in vivo efficacy, using an integrated approach combining cryogenic electron microscopy (cryo-EM), molecular dynamics (MD) simulations, signaling assays, and site-directed mutagenesis.
We identify a previously uncharacterized allosteric site for BMS-986187, a lipid-facing pocket formed by MOR transmembrane helices 2, 3, and 4, distinct from sites occupied by other known MOR PAMs or negative allosteric modulators.
BMS-986187 engages both receptor residues and a neighboring cholesterol molecule, suggesting a cooperative ligand-lipid mechanism.
Our studies pinpoint residues essential for allosteric modulation, while information-theory analysis of MD trajectories uncovers specific allosteric communication pathways linking the PAM site to both the orthosteric agonist DAMGO and the G protein interface.
Together, these findings redefine the landscape of MOR allosteric modulation by revealing a novel binding site, a potentially lipid-sensitive allosteric mechanism, and the molecular wiring of long-range communication within MOR.
This work provides a new molecular framework for the rational design of PAMs targeting opioid receptors with improved precision and possible therapeutic potential.
Related Results
Mechanism of µ-Opioid Receptor-Magnesium Interaction and Positive Allosteric Modulation
Mechanism of µ-Opioid Receptor-Magnesium Interaction and Positive Allosteric Modulation
Abstract
In the era of opioid abuse epidemics, there is an increased demand for understanding how opioid receptors can be allosterically modulate...
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
Abstract
Background
The United States is in the midst of an opioid overdose epidemic. We evaluated the temporal trends and risk...
Leftover Opioid Analgesics and Disposal Following Ambulatory Pediatric Surgeries in the Context of a Restrictive Opioid-Prescribing Policy
Leftover Opioid Analgesics and Disposal Following Ambulatory Pediatric Surgeries in the Context of a Restrictive Opioid-Prescribing Policy
BACKGROUND:
Opioid analgesics are commonly prescribed for postoperative analgesia following pediatric surgery and often result in leftover opioid analgesics in the home...
Review on allosteric modulators of dopamine receptors so far
Review on allosteric modulators of dopamine receptors so far
AbstractBackgroundContemporary research is predominantly directed towards allosteric modulators, a class of compounds designed to interact with specific sites distinct from the ort...
Opioid use in young veterans
Opioid use in young veterans
Purpose: Data suggest an increase in prescription opioid abuse in recent years. Young veterans represent a group with major risk factors for prescription opioid abuse. The objectiv...
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
(
2R,6R
)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice
ABSTRACT
Opioid addiction is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative af...
CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2–DOP receptor heterodimer
CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2–DOP receptor heterodimer
Opioid agonists have a broad range of effects on cells of the immune system, including modulation of the inflammatory response, and opioid and chemokine receptors are co-expressed ...
Opioid e-prescribing trends at discharge in a large pediatric health system
Opioid e-prescribing trends at discharge in a large pediatric health system
Objective: Legitimate opioid prescriptions have been identified as a risk factor for opioid misuse in pediatric patients. In 2014, Pennsylvania legislation expanded a prescription ...

